Orion Corp (ORNBV):企業の財務・戦略的SWOT分析

【英語タイトル】Orion Corp (ORNBV) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C3058)・商品コード:DATA904C3058
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:79
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Orion Corp (ORNBV) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Corp Key Recent Developments

Jul 18,2018: Orion: Half-year financial report January-June 2018
Jun 14,2018: Fermion’s new plant operational in Hanko-nearly 100% of production is exported
Jun 13,2018: Achema to cooperate with North China Power Engineering
Mar 20,2018: Orion Board of Arrangement
Feb 28,2018: Orion’s Statutory Co-operation Negotiations Completed

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Orion Corp – Key Facts 6
Orion Corp – Key Employees 7
Orion Corp – Key Employee Biographies 8
Orion Corp – Major Products and Services 9
Orion Corp – History 12
Orion Corp – Company Statement 15
Orion Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2 – Company Analysis 18
Company Overview 18
Orion Corp – Business Description 19
Business Segment: Diagnostics 19
Overview 19
Performance 19
Business Segment: Pharmaceuticals 19
Overview 19
Performance 19
Key Stats 20
Business Segment: Pharmaceuticals Sub-division: Animal Health 20
Overview 20
Performance 20
Business Segment: Pharmaceuticals Sub-division: Contract Manufacturing 20
Overview 20
Performance 20
Business Segment: Pharmaceuticals Sub-division: Fermion 20
Overview 20
Performance 21
Business Segment: Pharmaceuticals Sub-division: Proprietary Products 21
Overview 21
Performance 21
Business Segment: Pharmaceuticals Sub-division: Specialty Products 21
Overview 21
Performance 21
Geographical Segment: Finland 22
Performance 22
Geographical Segment: North America 22
Performance 22
Geographical Segment: Other Countries 22
Performance 22
Geographical Segment: Other Europe 22
Performance 22
Geographical Segment: Scandinavia 22
Performance 22
R&D Overview 22
Orion Corp – Corporate Strategy 23
Orion Corp – SWOT Analysis 24
SWOT Analysis – Overview 24
Orion Corp – Strengths 24
Orion Corp – Weaknesses 25
Orion Corp – Opportunities 26
Orion Corp – Threats 27
Orion Corp – Key Competitors 28
Section 3 – Company Financial Ratios 29
Financial Ratios – Capital Market Ratios 29
Financial Ratios – Annual Ratios 30
Performance Chart 33
Financial Performance 33
Financial Ratios – Interim Ratios 34
Financial Ratios – Ratio Charts 35
Section 4 – Company’s Lifesciences Financial Deals and Alliances 36
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Orion Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Orion Corp, Recent Deals Summary 38
Section 5 – Company’s Recent Developments 39
Jul 18, 2018: Orion: Half-year financial report January-June 2018 39
Jun 14, 2018: Fermion’s new plant operational in Hanko-nearly 100% of production is exported 52
Mar 20, 2018: Orion Board of Arrangement 53
Feb 28, 2018: Orion’s Statutory Co-operation Negotiations Completed 54
Feb 07, 2018: Orion Group Financial Statement Release for 2017 55
Jan 04, 2018: Orion to renew operating model of its laboratories 62
Nov 07, 2017: Professor Heikki Joensuu has been Appointed Vice President of Therapy area Oncology, R&D in Orion 63
Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 64
Apr 26, 2017: Orion Group Interim Report January–March 2017 73
Apr 11, 2017: Pharmaceutical leader Orion selects Determine to optimize their global Source-to-Contract effectiveness 74
Section 6 – Appendix 75
Methodology 75
Ratio Definitions 75
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Orion Corp, Key Facts 6
Orion Corp, Key Employees 7
Orion Corp, Key Employee Biographies 8
Orion Corp, Major Products and Services 9
Orion Corp, History 12
Orion Corp, Subsidiaries 16
Orion Corp, Key Competitors 28
Orion Corp, Ratios based on current share price 29
Orion Corp, Annual Ratios 30
Orion Corp, Annual Ratios (Cont...1) 31
Orion Corp, Annual Ratios (Cont...2) 32
Orion Corp, Interim Ratios 34
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Orion Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 37
Orion Corp, Recent Deals Summary 38
Currency Codes 75
Capital Market Ratios 75
Equity Ratios 76
Profitability Ratios 76
Cost Ratios 77
Liquidity Ratios 77
Leverage Ratios 78
Efficiency Ratios 78

List of Figures
Orion Corp, Performance Chart (2013 - 2017) 33
Orion Corp, Ratio Charts 35
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 36
Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 37

★調査レポート[Orion Corp (ORNBV):企業の財務・戦略的SWOT分析] (コード:DATA904C3058)販売に関する免責事項を必ずご確認ください。
★調査レポート[Orion Corp (ORNBV):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆